arrow
E

Evangelos Terpos

National and Kapodistrian University of Athens
H指数:106
被引数:5.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A Prospective Study of Familial Predisposition in Plasma Cell Dyscrasias

家族性易感性在浆细胞异常中的前瞻性研究

2026-07-220
OA
Efficacy and Safety of PD-1 Inhibitor-Based Regimens in Patients with Melanoma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

PD-1抑制剂为基础方案在黑色素瘤患者中的疗效与安全性:一项随机对照试验的系统评价与Meta分析

2026-06-180
OA
Prognostic value of MYD88/CXCR4 mutation allele fraction in Waldenström macroglobulinemia using a multiplex ddPCR assay

MYD88/CXCR4突变等位基因分数在瓦尔登斯特罗姆巨球蛋白血症中的预后价值:使用多重ddPCR测定法

2026-06-150
OAAI
Delving into tRNA-derived small RNAs in multiple myeloma: elevated 3′U-tRFSerTGA leads to poor disease prognosis

探讨多发性骨髓瘤中的tRNA衍生小RNA:升高的3′U-tRFSerTGA导致不良疾病预后

2026-05-010
OAAI
Real-World Experience with Approved CAR T-Cell Therapies Ciltacabtagene Autoleucel and Idecabtagene Vicleucel in 1272 Relapsed/Refractory Multiple Myeloma Patients

真实世界中经批准的CAR T细胞疗法Ciltacabtagene autoleucel和Idecabtagene vicleucel在1272例复发/难治性多发性骨髓瘤患者中的应用经验

Cancers
IF4.4
2026-04-030
OAAI
Clinical outcomes in newly diagnosed patients with Waldenström's macroglobulinaemia treated in a tertiary academic centre

新诊断的华氏巨球蛋白血症患者在三级学术中心治疗后的临床结局

2026-01-220
PRE
Daratumumab-based quadruplet for patients with extramedullary multiple myeloma: Results from the Phase II prospective EMN19 study
2026-01-080
OAAI
Belantamab mafodotin, lenalidomide and dexamethasone (BelaRd) in newly diagnosed intermediate-fit and frail myeloma

Belantamab mafodotin、lenalidomide和dexamethasone(BelaRd)在新诊断的中等适合和脆弱型骨髓瘤中

Blood
IF23.1
2025-12-080
PREAI
Corrigendum to “Evaluation of cumulative radiation burden and associated risk in smouldering multiple myeloma patients monitored using recurrent whole-body low-dose CT imaging”. [Phys. Med. 138 (2025) 105173]

勘误:“使用重复全身低剂量CT成像监测的冒烟性多发性骨髓瘤患者累积辐射负担及关联风险的评估”。[Phys. Med. 138 (2025) 105173]

2025-10-290
PRE
Randomized Phase III Study (ADMYRE) of Plitidepsin in Combination with Dexamethasone vs. Dexamethasone Alone in Relapsed/Refractory Multiple Myeloma: Results for Patients Aged <75 Years

ADMYRE随机Ⅲ期研究:评估普利地芬联合地塞米松与单用地塞米松治疗复发/难治性多发性骨髓瘤的疗效,结果针对年龄<75岁的患者群体。

Cancers
IF4.4
2025-10-290
OAAI
Bone disease burden does not impact overall survival in newly diagnosed patients with multiple myeloma − a single center, retrospective imaging analysis on 119 patients

骨疾病负担不影响新诊断多发性骨髓瘤患者的总生存期——一项基于119例患者的单中心、回顾性影像学分析

2025-10-250
OAAI